Lys-pro-val dimer, formulations and applications

Abstract

The present invention is directed to a system for treating uro-genital conditions. One aspect of this invention involves the treatment system comprising one or more polypeptides with a amino acid sequence including KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2) HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), for treatment of uro-genital conditions. The one or more polypeptides can also be a dimer formed from any of the amino acid sequence above. Uro-genital conditions can include infections, inflammation, or both. In one preferred embodiment of the invention, the uro-genital condition includes infection and/or inflammation of the vagina, vulva, urinary tract, penis, and/or the rectum. In another preferred embodiment of the invention, the one or more polypeptides are dissolved in a carrier. In another preferred embodiment of the invention, the one or more polypeptides are associated with a tampon for preventing toxic shock syndrome. In another preferred embodiment, the one or more polypeptides are associated with a contraceptive for prevention of sexually transmitted diseases or infections. In another preferred embodiment, the one or more polypeptides are associated with a suppository for insertion into the vagina or rectum.

What is claimed is:  
     
         1 . A uro-genital condition treatment system comprising: 
 a carrier;    at least one polypeptide including an amino acid sequence selected from a group consisting of KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing; and    wherein the carrier carries the at least one polypeptide.    
     
     
         2 . The uro-genital condition treatment system of  claim 1  wherein the at least one polypeptide includes a dimer formed from any amino acid sequence in the group in  claim 1 .  
     
     
         3 . The uro-genital condition treatment system of  claim 2  wherein the dimer is a KPV dimer.  
     
     
         4 . The uro-genital condition treatment system of  claim 1  wherein the amino acid sequence KPV (SEQ. ID. NO. 1), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) is located at the C-terminal of the at least one polypeptide.  
     
     
         5 . The uro-genital condition treatment system of  claim 1  wherein the amino acid sequence KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), includes at least one amino acid in the D-form.  
     
     
         6 . The uro-genital condition treatment system of  claim 1  wherein the at least one polypeptide is N-acetylated or C-amidated or both.  
     
     
         7 . The uro-genital condition treatment system of  claim 1  further comprises an applicator for applying the carrier to a site of the uro-genital condition.  
     
     
         8 . The uro-genital condition treatment system of  claim 7  wherein a part of the applicator is for insertion into the vagina, urethra, or rectum.  
     
     
         9 . The uro-genital condition treatment system of  claim 1  wherein the uro-genital condition is an infection, inflammation, or both.  
     
     
         10 . The uro-genital condition treatment system of  claim 1  wherein the uro-genital condition includes the presence of bacteria or fungi in a uro-genital area.  
     
     
         11 . The uro-genital condition treatment system of  claim 1  wherein the uro-genital condition includes the presence of a virus in a uro-genital area.  
     
     
         12 . The uro-genital condition treatment system of  claim 1  the uro-genital condition is caused by a bacterial infection or a fungal infection or both.  
     
     
         13 . The uro-genital condition treatment system of  claim 1  wherein the uro-genital condition is caused by a viral infection, bacterial infection, fungal infection, or any combination thereof.  
     
     
         14 . The uro-genital condition treatment system of  claim 10  wherein the bacteria is a gram-positive bacteria.  
     
     
         15 . The uro-genital condition treatment system of  claim 10  wherein the bacteria is from the genus of Staphylococcus.  
     
     
         16 . The uro-genital condition treatment system of  claim 10  wherein the bacteria is  Staphylococcus aureus.    
     
     
         17 . The uro-genital condition treatment system of  claim 10  wherein the fungi is from the genus Candida.  
     
     
         18 . The uro-genital condition treatment system of  claim 10  wherein the fungi is  Candida albicans.    
     
     
         19 . The uro-genital condition treatment system of  claim 11  wherein the virus is a HIV.  
     
     
         20 . The uro-genital condition treatment system of  claim 11  wherein the virus is HSV.  
     
     
         21 . The uro-genital condition treatment system of  claim 1  wherein the uro-genital condition is located in a female reproductive cavity or on a genitalia or both.  
     
     
         22 . The uro-genital condition treatment system of  claim 1  wherein the uro-genital condition is located in the urinary tract.  
     
     
         23 . The uro-genital condition treatment system of  claim 1  wherein the uro-genital condition is located on a penis.  
     
     
         24 . The uro-genital condition treatment system of  claim 1  wherein the uro-genital condition is located in a rectal cavity or on a rectal area or both.  
     
     
         25 . The uro-genital condition treatment system of  claim 1  wherein the uro-genital condition includes vaginitis.  
     
     
         26 . The uro-genital condition treatment system of  claim 1  wherein the uro-genital condition includes cystitis or urethritis.  
     
     
         27 . The uro-genital condition treatment system of  claim 1  wherein the uro-genital condition includes balanoposthitis.  
     
     
         28 . The uro-genital condition treatment system of  claim 1  wherein the carrier is a cream, an ointment, a balm, an aerosol foam, an aerosol spray, or a dissolvable pill.  
     
     
         29 . A tampon comprising: 
 an absorbent material;    at least one polypeptide including an amino acid sequence selected from the group consisting of KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing; and    wherein the absorbent material is associated with the at least one polypeptide.    
     
     
         30 . The tampon of  claim 29  wherein the at least one polypeptide includes a dimer formed from any amino acid sequence in the group in  claim 29 .  
     
     
         31 . The tampon of  claim 30  wherein the dimer is a KPV dimer.  
     
     
         32 . The tampon of  claim 29  wherein the amino acid sequence KPV (SEQ. ID. NO. 1), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) is located at the C-terminal of the at least one polypeptide.  
     
     
         33 . The tampon of  claim 29  wherein the amino acid KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4) includes at least one amino acid in the D-form.  
     
     
         34 . The tampon of  claim 29  wherein the at least one polypeptide is N-acetylated or C-amidated or both.  
     
     
         35 . A contraceptive comprising: 
 a barrier;    a carrier associated with the barrier;    at least one polypeptide including an amino acid sequence selected from the group consisting of KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing; and    wherein the carrier carries the at least one polypeptide.    
     
     
         36 . The contraceptive of  claim 35  wherein the at least one polypeptide includes a dimer formed from any amino acid sequence in the group in  claim 35 .  
     
     
         37 . The contraceptive of  claim 36  wherein the dimer is a KPV dimer.  
     
     
         38 . The contraceptive of  claim 35  wherein the amino acid KPV (SEQ. ID. NO. 1), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) is located at the C-terminal of the at least one polypeptide.  
     
     
         39 . The contraceptive of  claim 35  wherein the amino acid sequence KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4) includes at least one amino acid in the D-form.  
     
     
         40 . The contraceptive of  claim 35  wherein the at least one polypeptide is N-acetylated or C-amidated or both.  
     
     
         41 . The contraceptive of  claim 35  wherein the barrier is a condom, a diaphragm, or a sponge.  
     
     
         42 . A suppository comprising: 
 a carrier;    at least one polypeptide including an amino acid sequence selected from the group consisting of KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing; and    wherein the carrier carries the at least one polypeptide.    
     
     
         43 . The suppository of  claim 42  wherein the at least one polypeptide includes a dimer formed from any amino acid sequence in the group in  claim 42 .  
     
     
         44 . The suppository of  claim 43  wherein the dimer is a KPV dimer.  
     
     
         45 . The suppository of  claim 42  wherein the amino acid sequence KPV (SEQ. ID. NO. 1), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) is located at the C-terminal of the at least one polypeptide.  
     
     
         46 . The contraceptive of  claim 42  wherein the amino acid sequence KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4) includes at least one amino acid in the D-form.  
     
     
         47 . The suppository of  claim 42  wherein the at least one polypeptide is N-acetylated or C-amidated or both.  
     
     
         48 . A method of treating uro-genital condition comprising: 
 using at least one polypeptide including an amino acid sequence selected from the group consisting of KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing.    
     
     
         49 . The method of  claim 49  further comprising: 
 locally applying the at least one polypeptide at a site of the uro-genital condition.  
 
     
     
         50 . The method of  claim 49  wherein the local application is achieved through a suppository, a tampon, or a contraceptive.  
     
     
         51 . The method of  claim 49  wherein the local application is achieved through a cream, an ointment, a balm, a gel, an aerosol foam, an aerosol spray, or a dissolvable pill.  
     
     
         52 . The method of  claim 48  wherein the at least one polypeptide includes a dimer formed from any amino acid sequence in the group in  claim 48 .  
     
     
         53 . The method of  claim 52  wherein the dimer is a KPV dimer.  
     
     
         54 . The method of  claim 48  wherein the amino acid sequence KPV (SEQ. ID. NO. 1), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) is located at the C-terminal of the at least one polypeptide.  
     
     
         55 . The method of  claim 48  wherein the amino acid sequence KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4) includes at least one amino acid in the D-form.  
     
     
         56 . The method of  claim 48  wherein the at least one polypeptide is N-acetylated or C-amidated or both.  
     
     
         57 . A method of preventing toxic shock syndrome comprising: 
 using at least one polypeptide including an amino acid sequence selected from the group consisting of KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing.    
     
     
         58 . The method of  claim 57  wherein the toxic shock syndrome is associated with toxic shock syndrome toxin-1 produced by  Staphylococcus aureus.    
     
     
         59 . The method of  claim 57  further comprising: 
 locally applying the at least one polypeptide in the vagina.  
 
     
     
         60 . The method of  59  wherein the local application is achieved through a tampon.  
     
     
         61 . The method of  57  wherein the at least one polypeptide is associated with a tampon.  
     
     
         62 . A method for preventing infection from sexually transmitted diseases comprising: 
 using a contraceptive together with at least one polypeptide including an amino acid sequence selected from the group consisting KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing.    
     
     
         63 . A method of  claim 62  wherein the contraceptive is a condom, a diaphragm, or a sponge.  
     
     
         64 . A method of  claim 63  wherein at least one polypeptide is carried by a lubricant present on the condom.  
     
     
         65 . A method of treating an antibiotic resistant microorganism comprising: 
 using at least one polypeptide including an amino acid sequence selected from the group consisting of KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing.